Nexavar (Sorafenib, BAY43-9006)
Sponsors
Bayer
Conditions
CancerCarcinoma, HepatocellularCarcinoma, Non-Small-Cell LungCarcinoma, Renal CellCarcinoma, Renal Cell (Advanced)Chronic Myelogenous LeukemiaLung CancerMetastasis
Phase 1
Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin
CompletedNCT00562913
Start: 2007-12-31End: 2010-03-31Updated: 2013-11-26
Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors
CompletedNCT00606125
Start: 2007-05-31End: 2009-02-28Updated: 2014-06-23
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
CompletedNCT01069328
Start: 2006-07-31End: 2011-10-31Updated: 2013-11-13
Phase 2
Research Study for Patients With Metastatic Renal Cell Carcinoma
TerminatedNCT00110344
Start: 2005-11-30End: 2006-06-30Updated: 2013-10-11
Extension Program for Bay 43-9006
CompletedNCT00657254
Start: 2002-12-31End: 2005-06-30Updated: 2014-12-23
BAY43-9006 Phase II Study for Renal Cell Carcinoma
CompletedNCT00661375
Start: 2004-11-30End: 2006-03-31Updated: 2014-12-25
Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec
CompletedNCT00661180
Start: 2004-01-31End: 2005-02-28Updated: 2014-12-23
Phase 3
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
CompletedNCT00492986
Start: 2005-10-31End: 2008-11-30Updated: 2014-12-30
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
CompletedNCT00692770
Start: 2008-08-15End: 2014-11-28Updated: 2018-08-08